“I think this is an incredible time to be investing in biotech.” Dr. Simeon George, founder and CEO of SR One, joins Bloomberg Intelligence analyst Sam Fazeli to explain why biotech’s next cycle will be global, selective and unforgiving. George traces SR One’s evolution from one of pharma’s oldest corporate venture arms to an independent firm with more than $2 billion raised. The conversation explores why AI’s real test is cutting development time and attrition, not just discovering targets, while also laying out SR One’s view on oncology crowding, neuro’s blood-brain-barrier challenge, China’s accelerating role in drug innovation and the importance of building companies around medicines that can truly change standard of care.

<p>&ldquo;I think this is an incredible time to be investing in biotech.&rdquo; Dr. Simeon George, founder and CEO of SR One, joins Bloomberg Intelligence analyst Sam Fazeli to explain why biotech&rsquo;s next cycle will be global, selective and unforgiving. George traces SR One&rsquo;s evolution from one of pharma&rsquo;s oldest corporate venture arms to an independent firm with more than $2 billion raised. The conversation explores why AI&rsquo;s real test is cutting development time and attrition, not just discovering targets, while also laying out SR One&rsquo;s view on oncology crowding, neuro&rsquo;s blood-brain-barrier challenge, China&rsquo;s accelerating role in drug innovation and the importance of building companies around medicines that can truly change standard of care.</p>

Vanguards of Healthcare is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

<p>Vanguards of Healthcare is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.</p>

Vanguards of Healthcare by Bloomberg Intelligence

SR One Highlights Biotech's Latest Comeback Cycle

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/fe39bfbf-cd97-4f97-a731-b487007d869f/transcript